Buy this small stock before coming AI Tidal Wave

The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.

Get the name and ticker symbol for free - just click here.

Amy Schulman Biography and Net Worth

Director of Alnylam Pharmaceuticals

Amy W. Schulman is Independent Director of the Alnylam Pharmaceuticals, Inc. Ms. Schulman joined Polaris Partners, a venture capital firm, in August 2014. In July 2015, Ms. Schulman co-founded Lyndra, Inc., where she serves as the Chief Executive Officer and a director. In February 2017, Ms. Schulman became Chief Executive Officer of Olivo Laboratories, LLC and also serves as Executive Chair of SQZ Biotech. Since July 2014, Ms. Schulman has also been a senior lecturer at Harvard Business School. Ms. Schulman served as Chief Executive Officer of Arsia Therapeutics, Inc. from August 2014 to November 2016, when Arsia was acquired by Eagle Pharmaceuticals, Inc. Ms. Schulman was previously the Executive Vice President and General Counsel of Pfizer Inc., a global pharmaceutical company, from May 2008 to July 2014, where she also served as the Business Unit Lead for Pfizer’s Consumer Healthcare business from 2012 to 2013. Before joining Pfizer, she was a partner at DLA Piper. Ms. Schulman also serves as a director of Ironwood Pharmaceuticals, Inc. and Arsanis, Inc., and formerly served as a director of Blue Buffalo Pet Products, Inc. and BIND Therapeutics, Inc.

What is Amy W. Schulman's net worth?: The estimated net worth of Amy W. Schulman is at least $2.06 million as of May 29th, 2024. Ms. Schulman owns 8,436 shares of Alnylam Pharmaceuticals stock worth more than $2,060,493 as of July 1st. This net worth approximation does not reflect any other investments that Ms. Schulman may own. Learn More about Amy W. Schulman's net worth.
How do I contact Amy W. Schulman?: The corporate mailing address for Ms. Schulman and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Amy W. Schulman's contact information.
Has Amy W. Schulman been buying or selling shares of Alnylam Pharmaceuticals?: Amy W. Schulman has not been actively trading shares of Alnylam Pharmaceuticals in the last ninety days. Most recently, Amy W. Schulman sold 21,700 shares of the business's stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a transaction totalling $3,224,620.00. Following the completion of the sale, the director now directly owns 8,436 shares of the company's stock, valued at $1,253,589.60. Learn More on Amy W. Schulman's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Michael Bonney (Director), Jeffrey Dunn (CEO), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 112,501 shares worth more than $22,093,058.52. The most recent insider tranaction occured on June, 25th when CMO Pushkal Garg sold 2,103 shares worth more than $485,771.97. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 6/25/2024.

Amy W. Schulman Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/29/2024	Sell	21,700	$148.60	$3,224,620.00	8,436

Amy W. Schulman Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $243.32

$239.85

$246.06

50 Day Range

MA: $159.86

$143.31

$247.00

2 Week Range

Now: $243.32

$141.98

$252.87

Volume

1,491,626 shs

Average Volume

882,763 shs

Market Capitalization

$30.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37